{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:10:54Z","timestamp":1772010654892,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.7759\/cureus.104212","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:30:45Z","timestamp":1772008245000},"source":"Crossref","is-referenced-by-count":0,"title":["Midodrine Monotherapy in Refractory Hepatorenal Syndrome-Acute Kidney Injury: A Case Report"],"prefix":"10.7759","author":[{"given":"Timothy J","family":"Ford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Reffai Syed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert T","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.11.306","article-title":"Hepatorenal syndrome in cirrhosis","volume":"166","author":"Pose E","year":"2024","unstructured":"Pose E, Piano S, Juanola A, Gin\u00e8s P. Hepatorenal syndrome in cirrhosis. Gastroenterology. 2024, 166:588-604.e1. 10.1053\/j.gastro.2023.11.306","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018, 69:406-60. 10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo JG","year":"2017","unstructured":"Acevedo JG, Cramp ME. Hepatorenal syndrome: update on diagnosis and therapy. World J Hepatol. 2017, 9:293-9. 10.4254\/wjh.v9.i6.293","journal-title":"World J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.031","article-title":"Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting","volume":"81","author":"Nadim MK","year":"2024","unstructured":"Nadim MK, Kellum JA, Forni L, et al.. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024, 81:163-83. 10.1016\/j.jhep.2024.03.031","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin M","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al.. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015, 62:567-74. 10.1002\/hep.27709","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.033","article-title":"AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review","volume":"20","author":"Flamm SL","year":"2022","unstructured":"Flamm SL, Wong F, Ahn J, Kamath PS. AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review. Clin Gastroenterol Hepatol. 2022, 20:2707-16. 10.1016\/j.cgh.2022.08.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2023.0853","article-title":"Novel predictors of response to therapy with terlipressin and albumin in hepatorenal syndrome-acute kidney injury","volume":"37","author":"Narayanan V","year":"2024","unstructured":"Narayanan V, Devadas K, Sreesh S, et al.. Novel predictors of response to therapy with terlipressin and albumin in hepatorenal syndrome-acute kidney injury. Ann Gastroenterol. 2024, 37:81-8. 10.20524\/aog.2023.0853","journal-title":"Ann Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar A","year":"2010","unstructured":"Nazar A, Pereira GH, Guevara M, et al.. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010, 51:219-26. 10.1002\/hep.23283","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619825719","article-title":"Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2","volume":"7","author":"Nguyen-Tat M","year":"2019","unstructured":"Nguyen-Tat M, J\u00e4ger J, Rey JW, et al.. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J. 2019, 7:529-37. 10.1177\/2050640619825719","journal-title":"United European Gastroenterol J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/457613","article-title":"Hepatorenal syndrome: outcome of response to therapy and predictors of survival","volume":"2015","author":"Heidemann J","year":"2015","unstructured":"Heidemann J, Bartels C, Berssenbr\u00fcgge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015, 2015:457613. 10.1155\/2015\/457613","journal-title":"Gastroenterol Res Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v4.i2.277","article-title":"Management of hepatorenal syndrome","volume":"4","author":"Dundar HZ","year":"2015","unstructured":"Dundar HZ, Y\u0131lmazlar T. Management of hepatorenal syndrome. World J Nephrol. 2015, 4:277-86. 10.5527\/wjn.v4.i2.277","journal-title":"World J Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000671","article-title":"AASLD practice guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis","volume":"79","author":"Karvellas CJ","year":"2024","unstructured":"Karvellas CJ, Bajaj JS, Kamath PS, et al.. AASLD practice guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology. 2024, 79:1463-502. 10.1097\/HEP.0000000000000671","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2018.12.002","article-title":"Vasoconstrictors in hepatorenal syndrome - a critical review","volume":"18","author":"Mattos \u00c2Z","year":"2019","unstructured":"Mattos \u00c2Z, Schacher FC, Mattos AA. Vasoconstrictors in hepatorenal syndrome - a critical review. Ann Hepatol. 2019, 18:287-90. 10.1016\/j.aohep.2018.12.002","journal-title":"Ann Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Meta-analysis: terlipressin therapy for the hepatorenal syndrome","volume":"24","author":"Fabrizi F","year":"2006","unstructured":"Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006, 24:935-44. 10.1111\/j.1365-2036.2006.03086.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-IDDF.66","article-title":"IDDF2021-ABS-0034 midodrine as a secondary prophylaxis for hepatorenal syndrome","volume":"70","author":"Parikh P","year":"2021","unstructured":"Parikh P. IDDF2021-ABS-0034 midodrine as a secondary prophylaxis for hepatorenal syndrome. Gut. 2021, 70:10.1136\/gutjnl-2021-IDDF.66","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2012.060","article-title":"Terlipressin for hepatorenal syndrome","volume":"35","year":"2012","unstructured":"Terlipressin for hepatorenal syndrome. Aust Prescr. 2012, 35.128-35. 10.18773\/austprescr.2012.060","journal-title":"Aust Prescr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440644-midodrine-monotherapy-in-refractory-hepatorenal-syndrome-acute-kidney-injury-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:30:46Z","timestamp":1772008246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440644-midodrine-monotherapy-in-refractory-hepatorenal-syndrome-acute-kidney-injury-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.104212","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}